Pharmafile Logo
Pharmafocus logo
Advanced Search

prostate cancer

Showing 15 posts of 92 posts found.

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

July 4, 2025
Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …

News

Biocon Biologics gains EU approval for bone health therapies

July 4, 2025
Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …

News
money-2180330_960_720

Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology

June 20, 2025
Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer

Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …

News

Another Day Pharma announces successful Phase II trial results for BZ371A in post-prostatectomy erectile dysfunction 

May 22, 2025
Research and Development Another Day Pharma, Genito-Urinary system, clinical trial, erectile dysfunction, prostate cancer, prostatectomy

First-in-class therapeutic peptide BZ371A confirmed as effective and well-tolerated  20 May 2025. Another Day Pharma Ltd, a company developing innovative …

News
Press release

Third application for Orion’s prostate cancer drug submitted by partner Bayer

September 23, 2024
Bayer, Cancer, Oncology, orion, prostate cancer

Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …

News

First oral treatment for hormone-sensitive prostate cancer recommended by NICE

August 15, 2024
Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer

Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …

News

Full-Life Technologies’ IND application for prostate cancer cleared by FDA

May 30, 2024
Medical Communications Full-Life Technologies, IND, Oncology, prostate cancer

Full-Life Technologies has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application …

News
national-cancer-institute-kmvohcb-w5g-unsplash_1

First patient dosed in AdvanCell’s phase 1/2 trial for prostate cancer treatment

November 9, 2023
Research and Development AdvanCell, Cancer, Oncology, clinical trial, prostate cancer

AdvanCell has announced that the first patient has been dosed with 212Pb-ADVC001 in its phase 1/2 trial for the PSMA-positive …

News

Lynparza granted approval to treat prostate cancer in Japan

August 25, 2023
Research and Development Merck, Oncology, astra zeneca, prostate cancer

AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from the Japanese Ministry of Health, …

News

FDA approved Janssen’s Akeega for prostate cancer treatment

August 14, 2023
Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …

News
national-cancer-institute-kmvohcb-w5g-unsplash_1

FDA approves Pfizer’s HRR mCRPC drug

June 21, 2023
Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer

US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …

News

Medical cannabis formulation kills prostate cancer in laboratory tests

July 19, 2021
Sales and Marketing medical cannabis, prostate cancer

Apollon Formularies have announced its medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate …

News

New NICE recommendation for Astellas prostate cancer drug

June 8, 2021
Manufacturing and Production Astellas, NICE, prostate cancer

A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …

News
1c64f360-c5ef-43b6-bcef-13cede36f571

Lucida Medical gains CE marking for AI prostate cancer tech

June 1, 2021
Manufacturing and Production AI, MRI, NHS, prostate cancer

Cambridge-based AI company, Lucida Medical, has received CE marking for its new machine learning-based prostate cancer detection software, Prostate Intelligence …

News
janssen_latest_logo_on_sign_closer

Janssen sees promising PRO data for prostate cancer therapy

May 27, 2021
Janssen, prostate cancer

Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase III TITAN study in patients …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025